Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Antiviral Therapy for HBV in Solid Tumor Patients
NCT03887702Phase 3
Key facts
- Status
- Terminated
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Countries
- 2
- Sponsor
- SWOG Cancer Research Network
- Modality
- Small Molecules
- Conditions
- hepatitis B infection (HBV)
01
Overview
Phase 3, randomised, open-label trial of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir in hepatitis B infection (HBV), sponsored by SWOG Cancer Research Network. Started Jan 2020; status: terminated.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
This phase III trial studies the effect of hepatitis B antiviral (anti-HBV) therapy in preventing liver complications in patients with chronic or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing therapy for cancer are at an increased risk for changes in the liver which could be minor or severe. Anti-HBV therapy acts against infections caused by HBV and may help reduce the chance that HBV gets worse or comes back in patients receiving anti-cancer therapy for solid tumors.
Beyond the preview
Go deeper on NCT03887702.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03887702.